BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 19563866)

  • 21. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
    Huang H; Chang EJ; Ryu J; Lee ZH; Lee Y; Kim HH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):99-105. PubMed ID: 17052691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The proximal promoter of the human cathepsin G gene conferring myeloid-specific expression includes C/EBP, c-myb and PU.1 binding sites.
    Lennartsson A; Garwicz D; Lindmark A; Gullberg U
    Gene; 2005 Aug; 356():193-202. PubMed ID: 16019164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells.
    Liu J; Yang H; Liu W; Cao X; Feng X
    J Cell Biochem; 2005 Nov; 96(4):716-27. PubMed ID: 16052479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cooperation of CREB and NFAT is required for PTHrP-induced RANKL expression in mouse osteoblastic cells.
    Park HJ; Baek K; Baek JH; Kim HR
    J Cell Physiol; 2015 Mar; 230(3):667-79. PubMed ID: 25187507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter.
    Kitazawa R; Kitazawa S
    Biochem Biophys Res Commun; 2002 Jan; 290(2):650-5. PubMed ID: 11785948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.
    Koide M; Kinugawa S; Ninomiya T; Mizoguchi T; Yamashita T; Maeda K; Yasuda H; Kobayashi Y; Nakamura H; Takahashi N; Udagawa N
    J Bone Miner Res; 2009 Aug; 24(8):1469-80. PubMed ID: 19292614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoproterenol Increases RANKL Expression in a ATF4/NFATc1-Dependent Manner in Mouse Osteoblastic Cells.
    Baek K; Park HJ; Baek JH; Kim HR
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Nfatc1 regulation identifies an enhancer required for gene expression that is specific to pro-valve endocardial cells in the developing heart.
    Zhou B; Wu B; Tompkins KL; Boyer KL; Grindley JC; Baldwin HS
    Development; 2005 Mar; 132(5):1137-46. PubMed ID: 15689382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation.
    Kim JH; Kim K; Youn BU; Jin HM; Kim JY; Moon JB; Ko A; Seo SB; Lee KY; Kim N
    Biochem J; 2011 Jun; 436(2):253-62. PubMed ID: 21413932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The molecular understanding of osteoclast differentiation.
    Asagiri M; Takayanagi H
    Bone; 2007 Feb; 40(2):251-64. PubMed ID: 17098490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced osteoclastogenesis by mitochondrial retrograde signaling through transcriptional activation of the cathepsin K gene.
    Guha M; Srinivasan S; Koenigstein A; Zaidi M; Avadhani NG
    Ann N Y Acad Sci; 2016 Jan; 1364(1):52-61. PubMed ID: 25800988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.
    Ishida N; Hayashi K; Hattori A; Yogo K; Kimura T; Takeya T
    J Bone Miner Res; 2006 Jan; 21(1):48-57. PubMed ID: 16355273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of mouse RANKL gene expression by Runx2 and PKA pathway.
    Mori K; Kitazawa R; Kondo T; Maeda S; Yamaguchi A; Kitazawa S
    J Cell Biochem; 2006 Aug; 98(6):1629-44. PubMed ID: 16598781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter.
    Kitazawa S; Kajimoto K; Kondo T; Kitazawa R
    J Cell Biochem; 2003 Jul; 89(4):771-7. PubMed ID: 12858342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RANKL treatment releases the negative regulation of the poly(ADP-ribose) polymerase-1 on Tcirg1 gene expression during osteoclastogenesis.
    Beranger GE; Momier D; Rochet N; Quincey D; Guigonis JM; Samson M; Carle GF; Scimeca JC
    J Bone Miner Res; 2006 Nov; 21(11):1757-69. PubMed ID: 17002555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1.
    Yasui T; Hirose J; Tsutsumi S; Nakamura K; Aburatani H; Tanaka S
    J Bone Miner Res; 2011 Nov; 26(11):2665-71. PubMed ID: 21735477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway.
    Yoon SH; Ryu Jy; Lee Y; Lee ZH; Kim HH
    J Bone Miner Res; 2011 Jun; 26(6):1217-29. PubMed ID: 21611964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VapB as a regulator of osteoclastogenesis via modulation of PLCγ2-Ca(2+)-NFAT signaling.
    Choi SW; Yeon JT; Park KI; Lee CH; Youn BS; Oh J; Lee MS
    FEBS Lett; 2012 Feb; 586(3):263-9. PubMed ID: 22245675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of small interfering RNA for inhibition of lipopolysaccharide-induced osteoclast formation and cytokine stimulation.
    Fahid FS; Jiang J; Zhu Q; Zhang C; Filbert E; Safavi KE; Spångberg LS
    J Endod; 2008 May; 34(5):563-9. PubMed ID: 18436035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.